Literature DB >> 18237550

Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation.

Junjun Wang1, Bing Hu, Lingtao Kong, Hui Cai, Chunni Zhang.   

Abstract

BACKGROUND: Several studies suggest that lipoprotein (a) [Lp(a)] act as acute phase reactant and be associated with early atherosclerosis in rheumatoid arthritis (RA). Oxidized Lp(a) [ox-Lp(a)] and Lp(a) immune complex (IC) concentrations both increased in patients with coronary heart disease. We investigated Lp(a), ox-Lp(a) and Lp(a)-IC concentrations in RA patients and to explore the relationships with inflammatory disease activity markers.
METHODS: Plasma Lp(a), ox-Lp(a) and Lp(a)-IC concentrations, and inflammatory markers were analyzed in 54 patients with RA, including 23 active and 21 inactive RA, and 60 control subjects.
RESULTS: Lp(a) and ox-Lp(a) concentrations in active RA were higher than those in both inactive RA and control; Lp(a)-IC concentrations in active RA were also higher than inactive RA, while no difference was found in Lp(a), ox-Lp(a) and Lp(a)-IC concentrations between inactive RA and control. Lp(a) concentrations were found positively correlated with ox-Lp(a) and Lp(a)-IC concentrations, respectively; ox-Lp(a) concentrations were also related with Lp(a)-IC. Lp(a), ox-Lp(a) and Lp(a)-IC were all found positively related with C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), respectively.
CONCLUSIONS: Native, oxidized Lp(a) and Lp(a)-IC concentrations increased in active RA patients. Inflammation may induce the changes of Lp(a), resulting in increased ox-Lp(a) and Lp(a)-IC, and may play an important role in atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18237550     DOI: 10.1016/j.cca.2007.12.015

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Apolipoprotein(a) inhibits lipopolysaccharide-induced IL-6 secretion in human astrocytoma cell line by interfering with lipopolysaccharide signaling.

Authors:  Guglielmina Chimienti; Anna Mezzapesa; Grazia M Liuzzi; Tiziana Latronico; Gabriella Pepe
Journal:  Inflamm Res       Date:  2010-11-02       Impact factor: 4.575

2.  Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome.

Authors:  Ayman Jubran; Anna Zetser; Barak Zafrir
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

3.  Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.

Authors:  Andreja Rehberger Likozar; Mark Zavrtanik; Miran Šebeštjen
Journal:  Ann Med       Date:  2020-06-08       Impact factor: 4.709

Review 4.  Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings.

Authors:  Hasya Zinger; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

5.  A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis.

Authors:  I Missala; U Kassner; E Steinhagen-Thiessen
Journal:  Int J Rheumatol       Date:  2012-12-05

Review 6.  Lipoprotein (a): structure, pathophysiology and clinical implications.

Authors:  Raul Cavalcante Maranhão; Priscila Oliveira Carvalho; Celia Cassaro Strunz; Fulvio Pileggi
Journal:  Arq Bras Cardiol       Date:  2014-07       Impact factor: 2.000

7.  Apolipoprotein (a)/Lipoprotein(a)-Induced Oxidative-Inflammatory α7-nAChR/p38 MAPK/IL-6/RhoA-GTP Signaling Axis and M1 Macrophage Polarization Modulate Inflammation-Associated Development of Coronary Artery Spasm.

Authors:  Yen-Kuang Lin; Chi-Tai Yeh; Kuang-Tai Kuo; Iat-Hang Fong; Vijesh Kumar Yadav; Nicholas G Kounis; Patrick Hu; Ming-Yow Hung
Journal:  Oxid Med Cell Longev       Date:  2022-01-19       Impact factor: 6.543

Review 8.  Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.

Authors:  Sabina Ugovšek; Miran Šebeštjen
Journal:  Biomolecules       Date:  2021-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.